Skip to main content

Advertisement

SpringerLink
Log in

Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To scrutinize published data from small mono-centric studies and case reports which implicated high response rates and promising survival times for a combination therapy consisting of epifocal dinitrochlorobenzene (DNCB) and dacarbazine (DTIC) for metastasized melanoma. This therapy merges the effects of an allergic contact dermatitis elicited at the site of a cutaneous metastasis, and systemic chemotherapy.

Methods

We performed a retrospective survey with nine German centers and evaluated 72 patients treated from 1993 to 2005.

Results

The objective response rate in stage III melanoma (n = 39) was 62%. In contrast, only 9% objective responses were observed in 33 stage IV patients. Interestingly, more than half of patients with objective remissions remained progression-free for more than 1 year irrespective of the stage of disease.

Conclusions

Epifocal DNCB combined with DTIC is effective in patients with regionally metastasized melanoma not amenable to surgery or isolated limb perfusion, whereas in stage IV disease in spite of few durable remissions the addition of DNCB does not improve the therapeutic efficacy of DTIC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzales Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125

    Article  PubMed  CAS  Google Scholar 

  • Bach AG, Marsch WC, Richter C, Lübbe D, Helmbold P (2005) Langfristig lokal rezidiviertes malignes Melanom. Hautarzt 56:949–954

    Article  PubMed  CAS  Google Scholar 

  • Balch CM, Buzaid AC, Soong S-J, Atkins AB, Cascinelli N, Coit DC, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm FM, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Comittee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  • Becker JC, Kämpgen E, Bröcker EB (2000) Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 25:503–508

    Article  PubMed  CAS  Google Scholar 

  • Budzanowska E, Pawlicki M (1988) An attempt at topical DNCB immunomodulation in advanced malignant melanoma. Tumori 74:519–522

    PubMed  CAS  Google Scholar 

  • Burg G, Braun-Falco O (1977) 1-Chlor-2, 4-dinitrobenzol(DNCB)-Salbe zur Sensibilisierung, Testung und Behandlung von Patienten mit malignem Melanom. Dtsch Med Wochenschr 102:210–211

    PubMed  CAS  Google Scholar 

  • Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernsthoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751

    PubMed  CAS  Google Scholar 

  • Drepper H, Biess B, Hofherr B, Hundeiker M, Lippold A, Otto F, Padberg G, Peters A, Wiebelt H (1993) The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide. Cancer 71:1239–1246

    Article  PubMed  CAS  Google Scholar 

  • Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos N, Plager C, Burgess A, Bedikian A, Ring S, Dong Q, Glassman A, Balch CM, Benjamin RS (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103–1111

    PubMed  CAS  Google Scholar 

  • Flaherty LE, Liu PY, Unger J, Sondak VK (1997) Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 20:600–604

    Article  PubMed  CAS  Google Scholar 

  • Göring HD, Ziemer A, Kröning Y, Trebing D, Kämpgen E, Bröcker EB (1998) Effective combined immunotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma. Melanoma Res 8:379

    Article  PubMed  Google Scholar 

  • Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE, Rassner G (1992) The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66:856–861

    PubMed  CAS  Google Scholar 

  • Illig L, Paul E (1976) Unspezifische epifokale Immuntherapie des malignen Melanoms der Haut mit DNCB nach Malek-Mansour. Hautarzt 27:579–587

    PubMed  CAS  Google Scholar 

  • Illig L, Paul E, Bödeker RH (1984) Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years). Anticancer Res 4:293–298

    PubMed  CAS  Google Scholar 

  • Inbar M, Merimsky O, Stein JA (1996) DNCB for local control of malignant melanoma: don’t forget a winning horse. Melanoma Res 6:457–459

    Article  PubMed  CAS  Google Scholar 

  • Junghans V, Menzel S, Rünger TM (1998) Erfolgreiche Therapie mit Dacarbazin und lokaler Applikation des Kontaktallergens Dinitrochlorbenzol bei therapieresistentem, in-transit- und fernmetastasiertem Melanom. Aktuelle Derm 24:332–335

    Google Scholar 

  • Khayat D, Bernard-Marty C, Meric J-B, Rixe O (2002) Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol 20:2411–2414

    PubMed  CAS  Google Scholar 

  • Kroon BBR, Noorda EM, Vrouenraets BC, Nieweg OE (2002) Isolated limb perfusion for melanoma. J Surg Oncol 79:252–255

    Article  PubMed  Google Scholar 

  • Loth H, Ehring F (1978) Die Behandlung des malignen Melanoms mit Dinitrochlorbenzol-Salbe. Hautarzt 29:141–146

    PubMed  CAS  Google Scholar 

  • Malek-Mansour S (1973) Remission of melanoma with DNCB treatment. Lancet 2:503–504

    Article  PubMed  CAS  Google Scholar 

  • Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62–70

    Article  PubMed  CAS  Google Scholar 

  • Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166

    PubMed  CAS  Google Scholar 

  • von Nida J, Quirk C (2003) Successful treatment of in-transit metastases using topical 2–4 dinitrochlorobenzene. Australas J Dermatol 44:277–280

    Article  Google Scholar 

  • Rümke P (1992) Melanoma treatment: a key role for immunotherapy with chemotherapy. Medicographia 14:47–49

    Google Scholar 

  • Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570

    Article  PubMed  CAS  Google Scholar 

  • Schuler-Thurner B, Schuler G (2005) Vaccination therapy of melanoma. JDDG 3:630–645

    Article  PubMed  Google Scholar 

  • Strobbe LJA, Hart AAM, Rümke Ph, Israels SP, Nieweg OE, Kroon BBR (1997) Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 7:507–512

    Article  PubMed  CAS  Google Scholar 

  • Trcka J, Kämpgen E, Becker JC, Schwaaf A, Bröcker EB (1998) Immunochemotherapie des malignen Melanoms: Epifokale Applikation von Dinitrochlorobenzol (DNCB) kombiniert mit systemischer Chemotherapie mit Dacarbazin (DTIC). Hautarzt 49:17–22

    Article  PubMed  CAS  Google Scholar 

  • Trefzer U, Sterry W (2005) Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology 211:370–371

    Article  PubMed  Google Scholar 

  • Truchetet F, Heid E, Friedel J, Chartier C, Grosshans E (1989) D.N.C.B. for malignant melanoma: significance in the treatment strategy. Anticancer Res 9:1531–1536

    PubMed  CAS  Google Scholar 

  • Wack C, Becker JC, Bröcker EB, Lutz WK, Fischer WH (2001) Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model. Melanoma Res 11:247–253

    Article  PubMed  CAS  Google Scholar 

  • Wack C, Kirst A, Becker JC, Lutz WK, Bröcker EB, Fischer WH (2002) Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. Cancer Immunol Immunother 51:431–439

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Würzburg, Josef-Schneider Str. 2, 97080, Würzburg, Germany

    P. Terheyden, A.-K. Kortüm, J. C. Becker & E.-B. Bröcker

  2. Department of Dermatology, Hornheide Clinic, Dorbaumstraße 300, 48157, Münster, Germany

    H.-J. Schulze

  3. Department of Dermatology, University of Heidelberg, Voßstraße 2, 69115, Heidelberg, Germany

    B. Durani

  4. Department of Dermatology, Technical University of Munich am Biederstein, Biedersteiner Straße 29, 80802, Munich, Germany

    R. Remling

  5. Department of Dermatology, University of Cologne, Joseph-Stelzmann-Str. 9, 50931, Cologne, Germany

    C. Mauch

  6. Department of Dermatology, University of Göttingen, von-Siebold-Str. 3, 37075, Göttingen, Germany

    V. Junghans

  7. Department of Dermatology, Klinische Kooperationseinheit Dermatologische Onkologie des Deutschen Krebsforschungszentrums, Theodor-Kutzer Ufer 1, 68135, Mannheim, Germany

    D. Schadendorf

  8. Department of Dermatology, Klinikum of Dortmund, Beurhausstraße 40, 44137, Dortmund, Germany

    U. Beiteke

  9. Department of Dermatology, University of Greifswald, Fleischmannstraße 42–44, 17487, Greifswald, Germany

    M. Jünger

Authors
  1. P. Terheyden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.-K. Kortüm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-J. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Durani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Remling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Mauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Junghans
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U. Beiteke
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Jünger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. C. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E.-B. Bröcker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Terheyden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terheyden, P., Kortüm, AK., Schulze, HJ. et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol 133, 437–444 (2007). https://doi.org/10.1007/s00432-006-0182-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-006-0182-9

Keywords

Search

Navigation